-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 26, 2021, Yichang Dongyangguang announced that insulin glargine was officially approved for listing, becoming the fourth domestic company to obtain the registration approval for this product after Ganli Pharmaceutical, United Laboratories, and Tonghua Dongbao
.
It is understood that Dongyang Sunshine’s insulin project was established in 2008 for research and development, with a total planned production capacity of 3,000 kilograms of raw materials per year and 200 million preparations, covering a variety of raw materials and preparations such as recombinant human insulin, insulin glargine, and insulin aspart
.
According to the company's plan, the insulin glargine injection produced by Dongyang Sunshine will be launched in the United States in 2023
.
In the next two to three years, the fourth-generation insulin glutathione will be approved for marketing
.
Insulin glargine is a new type of insulin analogue with long-acting effect, no peak blood concentration, and smoothly lowering the blood sugar of patients.
The original research company of this product is Sanofi, which was issued by the United States in April and June 2000, respectively.
Food and Drug Administration (FDA) and European Medical Products Review Board approved for diabetes
.
And it went on the market in China in 2004 under the trade name Laid time
.
Among domestic companies, Ganli Pharmaceutical was approved for listing in 2005.
Subsequently, United Laboratories and Tonghua Dongbao were approved in 2016 and 2019, respectively
.
In addition to Dongyang Sunshine, four companies including Boao Biology, Wanbang Biochemical, Shandong New Times Pharmaceutical, and Eli Lilly are also in the process of listing applications
.
The number of diabetic patients in China is huge, and the demand for diabetes treatment drugs including insulin is also increasing
.
According to data from Ai Kunwei China, the sales amount of drugs in the diabetes field in China in 2020 is about 4.
66 billion U.
S.
dollars, an increase of 7.
1% compared with 2019.
Among them, the sales amount of human insulin and its analogs accounted for about the total market sales of diabetes drugs.
46.
1% is the main type of medicine used in the field of diabetes treatment
.
It is reported that the product is a biological drug approved by Dongyang Sunshine Group, and the accumulated research and development expenses are about 153 million yuan
.
In addition, the group has a comprehensive plan in the field of diabetes treatment and has laid out a complete product line
.
The successful listing of this product is beneficial to the expansion of the Group's endocrine and metabolic treatment business and further enriches the Group's product portfolio
.
It is worth mentioning that, according to the sixth batch of insulin special collection list announced in September, the collection list involves 81 products from 10 companies, including Novo Nordisk, Sanofi, Ganli Pharmaceutical, and Tonghua Pharmaceutical companies such as Dongbao and Yichang Dongyangguang have large products with sales exceeding 1 billion
.
It means that insulin with a market size of more than 20 billion yuan will start the era of centralized procurement
.
Judging from the list, the "attack" of insulin glargine by domestic enterprises is a bright spot
.
In this centralized procurement list, 7 companies including Ganli Pharmaceutical, United Laboratories, Tonghua Dongbao, Jiangsu Wanbang, Dongyang Sunshine, etc.
have declared a total of 43 insulin products, including 5 insulin glargine products currently on the market in China , Respectively are "Lai De Shi", "Lai You Shi", "Chang Xiulin", "You Le Ling" and "Chang Shu Lin"
.
The industry pointed out that this means that the original Sanofi will form a "3+1" pattern with three domestic companies, Ganli Pharmaceutical, United Laboratories, and Tonghua Dongbao
.
According to data from Meinenet, in 2020, the sales of insulin glargine injection in China's public medical institutions will exceed 6.
8 billion yuan
.
In terms of market share, Sanofi and other foreign-funded companies have obvious advantages, and Ganli Pharmaceutical's restructuring insulin glargine also accounts for a certain share
.
The industry predicts that there is a lot of room for domestic substitution of this product
.
With the implementation of centralized procurement across the country, the insulin market will face pressure to reduce prices in the short term, but in the long run, centralized procurement may help domestic companies to develop the third-generation insulin market
.
.
It is understood that Dongyang Sunshine’s insulin project was established in 2008 for research and development, with a total planned production capacity of 3,000 kilograms of raw materials per year and 200 million preparations, covering a variety of raw materials and preparations such as recombinant human insulin, insulin glargine, and insulin aspart
.
According to the company's plan, the insulin glargine injection produced by Dongyang Sunshine will be launched in the United States in 2023
.
In the next two to three years, the fourth-generation insulin glutathione will be approved for marketing
.
Insulin glargine is a new type of insulin analogue with long-acting effect, no peak blood concentration, and smoothly lowering the blood sugar of patients.
The original research company of this product is Sanofi, which was issued by the United States in April and June 2000, respectively.
Food and Drug Administration (FDA) and European Medical Products Review Board approved for diabetes
.
And it went on the market in China in 2004 under the trade name Laid time
.
Among domestic companies, Ganli Pharmaceutical was approved for listing in 2005.
Subsequently, United Laboratories and Tonghua Dongbao were approved in 2016 and 2019, respectively
.
In addition to Dongyang Sunshine, four companies including Boao Biology, Wanbang Biochemical, Shandong New Times Pharmaceutical, and Eli Lilly are also in the process of listing applications
.
The number of diabetic patients in China is huge, and the demand for diabetes treatment drugs including insulin is also increasing
.
According to data from Ai Kunwei China, the sales amount of drugs in the diabetes field in China in 2020 is about 4.
66 billion U.
S.
dollars, an increase of 7.
1% compared with 2019.
Among them, the sales amount of human insulin and its analogs accounted for about the total market sales of diabetes drugs.
46.
1% is the main type of medicine used in the field of diabetes treatment
.
It is reported that the product is a biological drug approved by Dongyang Sunshine Group, and the accumulated research and development expenses are about 153 million yuan
.
In addition, the group has a comprehensive plan in the field of diabetes treatment and has laid out a complete product line
.
The successful listing of this product is beneficial to the expansion of the Group's endocrine and metabolic treatment business and further enriches the Group's product portfolio
.
It is worth mentioning that, according to the sixth batch of insulin special collection list announced in September, the collection list involves 81 products from 10 companies, including Novo Nordisk, Sanofi, Ganli Pharmaceutical, and Tonghua Pharmaceutical companies such as Dongbao and Yichang Dongyangguang have large products with sales exceeding 1 billion
.
It means that insulin with a market size of more than 20 billion yuan will start the era of centralized procurement
.
Judging from the list, the "attack" of insulin glargine by domestic enterprises is a bright spot
.
In this centralized procurement list, 7 companies including Ganli Pharmaceutical, United Laboratories, Tonghua Dongbao, Jiangsu Wanbang, Dongyang Sunshine, etc.
have declared a total of 43 insulin products, including 5 insulin glargine products currently on the market in China , Respectively are "Lai De Shi", "Lai You Shi", "Chang Xiulin", "You Le Ling" and "Chang Shu Lin"
.
The industry pointed out that this means that the original Sanofi will form a "3+1" pattern with three domestic companies, Ganli Pharmaceutical, United Laboratories, and Tonghua Dongbao
.
According to data from Meinenet, in 2020, the sales of insulin glargine injection in China's public medical institutions will exceed 6.
8 billion yuan
.
In terms of market share, Sanofi and other foreign-funded companies have obvious advantages, and Ganli Pharmaceutical's restructuring insulin glargine also accounts for a certain share
.
The industry predicts that there is a lot of room for domestic substitution of this product
.
With the implementation of centralized procurement across the country, the insulin market will face pressure to reduce prices in the short term, but in the long run, centralized procurement may help domestic companies to develop the third-generation insulin market
.
